Home › Trials › NCT06363435
Clinical trial Recruiting at 2 sites Observational Ages 20 to 120 Men only

AI-based measurement of tumor burden in prostate cancer using PET-CT scans

Official title: The Prognostic Value of AI-based Measurements of Tumour Burden in PSMA PET-CT in Patients With Prostate Cancer

Run by Skane University Hospital · NCT06363435 · Data updated 2026-11-12

This study is testing a new AI method to see how well it can measure tumor size in prostate cancer patients using special PET-CT scans to help understand their chances of survival.

More Prostate Cancer trials

Quick facts

Study typeObservational
Ages20 Years to 120 Years
SexMen only
Enrollment1500 (estimated)
SponsorSkane University Hospital
Academic / other
Locations2 sites (Lund and 1 other locations)
StatusRecruiting
StartedMarch 29, 2024
Main results expectedMarch 2031
Study endsMarch 2033
Registry record updatedApril 28, 2026
Trial IDNCT06363435 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are men diagnosed with high-risk prostate cancer who are referred for a clinically indicated 18F-PSMA-1007 PET-CT scan.

Probably not a fit

Patients under 20 years old will not benefit from this study as they are excluded from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of an AI-based method for automatically calculating tumor burden in prostate cancer patients using 18F-PSMA-1007 PET-CT scans. The study will measure tumor volume and uptake in various locations, including the prostate, pelvic lymph nodes, distant lymph nodes, and bones. Patients referred for either initial staging of high-risk prostate cancer or due to biochemical recurrence will be included. The data collected will be analyzed over a five-year follow-up period to assess its correlation with overall survival and progression-free survival.

Why it matters

Potential benefit: If successful, this study could enhance the accuracy of tumor burden assessment, leading to improved treatment strategies and outcomes for prostate cancer patients.

How similar studies have gone: While the use of AI in medical imaging is gaining traction, this specific approach to measuring tumor burden in prostate cancer using PSMA PET-CT scans is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden

Exclusion Criteria:

* Patients under 20 years old

Where it's running

  • Skåne University Hospital
    Lund, Sweden     Recruiting
  • Skåne university hospital
    Malmö, Sweden     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Skane University Hospital 21
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.